Stereotactic radiotherapy

Lederman G, Arbit E, Odaimi M, Wertheim S, Lombardi E. Recurrent glioblastoma multiforme potential benefits using fractionated stereotactic radiotherapy and concurrent taxol. Stereotact Fund Neurosurg 1997 69(1—4 Pt 2) 162-174. 

IdUrd loaded microparticles within the tumor might increase the lethal effects of y-radiation of malignant cells having incorporated IdUrd. The particles can be administered by stereotactic injection, a precise surgical injection technique [207]. This approach requires microparticles of 40-50 pm in size releasing in vivo their content over 6 weeks, the standard period during which a radiotherapy course must be applied. 

Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G (2001) Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol 22 1316-1324. 

Lax I, Blomgren H, Naslund I et al (1994) Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33 677-683... 

External beam radiotherapy (including three-dimensional radiotherapy, intensity modulated radiotherapy, and extracranial stereotactic radiotherapy) is the most common way radiation is used to eradicate solid tumors, often with combined chemotherapy. The key limitation of external beam radiotherapy is the tolerance of normal liver parenchyma to radiation, which is much less than the dose required to control the liver tumors. Direct implantation of radionuclides into the tumor (brachytherapy) using interstitial seeds... 

Zimmermann FB, Geinitz H, Schill S, et al (2006) Stereotactic hypofractionated radiotherapy in stage I (Tl-2 NO MO) non-small-cell lung cancer (NSCLC). Acta Oncol 45 796-801... 

Improved results appear to be seen, e.g., in early clinical trials with stereotactic radiotherapy for early stage non-small cell lung cancer. These improvements are likely to result from several different developments that influence our ability to stage tumors, to define the target volume, to predict target volume movement during treatment, and to administer highly conformal treatment in a precise manner. 

Onishi et al. 2004 Non-small cell lung cancer stage I Hypofractionated stereotactic radiotherapy Crude rate of local-disease recurrence 13.5% 5-Year cause-specific survival 78%... 

Milker-Zabel et al. 2005 Meningioma grade I vs. II Stereotactic radiotherapy 5-Year recurrence-free survival 90.5 vs. 89%... 

Selch et al. 2004 Meningioma grade I/II Stereotactic radiotherapy 3-Year local control 97%... 

Delivery of sophisticated local treatment can only yield a survival advantage for patients with truly localized disease, or those with controlled or controllable systemic disease. The success of stereotactic radiotherapy, e.g., for early-stage non-small cell lung cancer (NSCLC) is critically dependent on the correct identification of node-negative patients. For this purpose, a hybrid PET-CT scanner and the tracer FDG might be used. Correct staging is also required for other diseases commonly treated with high-dose radiotherapy such as prostate cancer. In numerous chnical trials, PET and... 

Fig 20.2. Treatment planning CT scans displaying the isodose distributions in a patient with a single liver metastasis treated with fractionated stereotactic radiotherapy left side, dose prescribed to the 60% isodose line, which is shown in green)... 

Milker-Zabel S, Zabel A, Schulz-Ertner D et al (2005) Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 61 809-816... 

Selch MT, Ahn E, Laskari A et al (2004) Stereotactic radiotherapy for treatment of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 59 101-111... 

Gramaglia A, Loi GF, Mongioj V, Baronzio GF. Increased survival in brain metastatic patients treated with stereotactic radiotherapy, omega three fatty acids and bioflavonoids. Anticancer Res 1999 19(6C) 5583 5586. 

The glioblastoma multiforme (GBM) is the most common and deadly type of brain tumour, with a median life expectancy of twelve months after diagnosis. The data from a recent non-randomised phase II clinical trial by the team of Andreas Jordan have shown improvements in survival times after a combined treatment of magnetic hyperthermia with 12 nm amino-silane-coated magnetite nanoparticles and fractioned stereotactic radiotherapy. After going through both the corresponding feasibility and... 

---